Immutep surges on positive data from cancer therapy study

Immutep

17/05/2023 16:21

** U.S.-listed shares of Australia-based Immutep Ltd
 IMMP.O  surge 36.76% to $2.17 
    ** Stock set for its biggest one-day pct jump in over two
years, if gains hold 
    ** Co says its lead candidate eftilagimod in combination
with Merck & Co. Inc's  MRK.N  Keytruda prolonged the lives of
patients with a type of lung cancer in a mid-stage study   
    ** Co plans to release more data on the study later this
year
    ** Including session gain, Immutep's U.S.-listed stock up
~24% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))